Stocks · News reference

Faeth Therapeutics shares are trading lower after the company reported a wider net loss for the second quarter driven by a sharp increase in expenses.

Aug 4, 2026, 2:22 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 21, 2026, 11:46 AMAvi Kapoor
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. AVGO receives Outperform rating with $455 PT.
Read original at benzinga
AVGO BLDR FTH HUBB NUVB
BenzingaAug 21, 2026, 9:54 AMBenzinga Newsdesk
Needham Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $56
Needham analyst Gil Blum initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $56.
Read original at benzinga
FTH
BenzingaAug 17, 2026, 11:33 AMBenzinga Newsdesk
Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer
— Fast Track designation applies to sapanisertib and serabelisib (PIKTOR) in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR
Read original at benzinga
FTH
BenzingaAug 11, 2026, 12:17 PMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $60 price target.
Read original at benzinga
FTH